Microscopic Polyangiitis Epidemiology Forecast 2026-2035

Microscopic polyangiitis is a rare antineutrophil cytoplasmic antibody-associated vasculitis affecting small vessels. According to Muhammad F. Hashmi et al. (2024), the global incidence is approximately 20 cases per million population. As per a systematic review, prevalence is about 39.2 per million worldwide. According to microscopic polyangiitis epidemiology forecast, disease burden remains low but clinically significant.

Microscopic Polyangiitis Epidemiology Forecast Report Coverage

The analyst's “Microscopic Polyangiitis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of microscopic polyangiitis. It projects the future incidence and prevalence rates of microscopic polyangiitis cases across various populations. The study covers age, gender, and type as major determinants of the microscopic polyangiitis population. The report highlights patterns in the prevalence of microscopic polyangiitis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of microscopic polyangiitis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Microscopic Polyangiitis Understanding: Disease Overview

Microscopic polyangiitis (MPA) is a rare, systemic autoimmune disease characterized by inflammation of small blood vessels, a condition known as vasculitis. It is commonly associated with anti-neutrophil cytoplasmic antibodies (ANCA), particularly myeloperoxidase-ANCA, which trigger immune-mediated vessel damage. The disease primarily affects organs such as the kidneys, lungs, skin, and peripheral nerves, often leading to rapidly progressive glomerulonephritis and pulmonary complications. MPA does not typically involve granuloma formation, distinguishing it from other vasculitides.

Microscopic Polyangiitis Epidemiology Perspective

The microscopic polyangiitis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the microscopic polyangiitis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for microscopic polyangiitis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to DynaMedex, microscopic polyangiitis is part of ANCA-associated vasculitis with a global prevalence of 200-400 cases per million; specifically, MPA prevalence ranges from 2.7 to 94 per million, while higher rates are observed in White populations, particularly in Northern Europe.
• As per the Muhammad F. Hashmi et al., 2024, the global incidence of MPA is estimated at 20 cases per million, while a Rochester, Minnesota study reported ANCA-associated vasculitis incidence of 3.3 per 100,000 annually and prevalence of 42.1 per 100,000, with GPA and MPA each contributing approximately 1.5 per 100,000.
• According to DynaMedex, Vasculitis UK, and Muhammad F. Hashmi et al., 2024, MPA primarily affects older adults, with median onset between 50 and 60 years and median diagnosis around 65 years, while peak onset occurs between 65 and 74 years, though cases can arise at any age.
• As per the DynaMedex, Vasculitis UK, and LISA ROSENBERG et al., 2023, MPA demonstrates near-equal gender distribution overall; however, some cohorts show slight male predominance, while one study reported 68% female patients, indicating variability in gender patterns across populations.
• According to Muhammad F. Hashmi et al., 2024, DynaMedex, and LISA ROSENBERG et al., 2023, MPA is more common in Asian countries such as China and Japan, shows increasing prevalence due to improved ANCA testing, and represents 8.8% of ANCA vasculitis cases, with outcomes improving due to earlier diagnosis and management.

Country-wise Microscopic Polyangiitis Epidemiology

The microscopic polyangiitis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Overall, the epidemiology of microscopic polyangiitis (MPA) demonstrates regional variability across the regions. According to the Vasculitis Foundation, the annual incidence in the United States is approximately 1.5 cases per 100,000 population, while as per Muhammad F. Hashmi et al., 2024, ANCA-associated vasculitis incidence is about 3.3 per 100,000 with a prevalence of 42.1 per 100,000, including MPA. In Europe, incidence rates are comparable, typically ranging between 1-2 per 100,000. As per available evidence, Japan shows a relatively higher occurrence, aligning with reports that MPA is more common in Asian populations, whereas data from India remain limited but indicate rarity with increasing recognition.

Microscopic Polyangiitis: Treatment Overview

The management of microscopic polyangiitis focuses on inducing and maintaining remission while preventing organ damage. Initial therapy typically involves high-dose corticosteroids combined with immunosuppressive agents such as cyclophosphamide or rituximab. Rituximab, a monoclonal antibody targeting B cells, has become a preferred option in many cases due to its efficacy and safety profile. For maintenance therapy, lower doses of corticosteroids are used alongside agents like azathioprine or methotrexate. In severe cases, particularly with renal failure or pulmonary hemorrhage, plasma exchange may be considered. Early diagnosis and prompt treatment are critical to improving patient outcomes and reducing relapse rates.

Key Questions Answered

• What are the key findings of microscopic polyangiitis epidemiology in the 8 major markets?
• What will be the total number of patients with microscopic polyangiitis across the 8 major markets during the forecast period?
• What was the country-wise microscopic polyangiitis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of microscopic polyangiitis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of microscopic polyangiitis during the forecast period of 2026-2035?
• What are the currently available treatments for microscopic polyangiitis?
• What are the risks, signs, symptoms, and unmet needs of microscopic polyangiitis?

Scope of the Microscopic Polyangiitis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of microscopic polyangiitis based on several factors.
• Microscopic Polyangiitis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The microscopic polyangiitis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.